NCT06486363View on ClinicalTrials.gov

Comparison of the Antiplatelet Efficacy of Aspirin Combined With Clopidogrel and Aspirin Combined With Half-dose Ticagrelor in Patients With Unruptured Intracranial Aneurysms With Normal CYP2C19 Metabolizer Phenotype

PHASE4Not yet recruitingINTERVENTIONAL

Enrollment

196

Participants

Timeline

Start Date

August 1, 2024

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2027

Conditions

Intracranial AneurysmsAntiplatelet Drugs

Interventions

DRUG

Aspirin combined with clopidogrel

Participants in this group shall take Aspirin (100 mg/day) + clopidogrel (75 mg/day) for at least 5 days before receiving stent-assisted coil embolization, and take same medication for 6 months after endovascular treatment

DRUG

Aspirin combined with half-dose ticagrelor

Participants in this group shall take Aspirin (100 mg/day) + half dose of ticagrelor (45 mg, 12 hours/time), at least for 3 days before receiving stent-assisted coil embolization, and take same medication for 6 months after endovascular treatment

All Listed Sponsors

lead

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

OTHER

NCT06486363 - Comparison of the Antiplatelet Efficacy of Aspirin Combined With Clopidogrel and Aspirin Combined With Half-dose Ticagrelor in Patients With Unruptured Intracranial Aneurysms With Normal CYP2C19 Metabolizer Phenotype | Biotech Hunter | Biotech Hunter